Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Trial Details
- NCT ID
- NCT06293898
- Phase
- PHASE1
- Sponsor
- SystImmune Inc.
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Locations (sample)
- Birmingham, Alabama, United States|33.52066,-86.80249
- Duarte, California, United States|34.13945,-117.97729
- Los Angeles, California, United States|34.05223,-118.24368
- San Diego, California, United States|32.71571,-117.16472
- Miami, Florida, United States|25.77427,-80.19366
Key Eligibility Criteria
- Age: ≥18 years
- Has a life expectancy of ≥3 months
- Has documented locally advanced or metastatic HER2expressing (IHC 1+ to 3+ and/or HER2 gene amplification or activating mutation in tumor specimen …
- Cohort 1: Subjects with HER2 expression in endometrial cancers (EC)
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →